- Home
- PRQR
as 05-21-2025 4:00pm EST
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
| Founded: | 2012 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 309.5M | IPO Year: | 2014 |
| Target Price: | $9.00 | AVG Volume (30 days): | 573.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $4.62 | Next Earning Date: | 05-08-2025 |
| Revenue: | $21,212,711 | Revenue Growth: | 85.91% |
| Revenue Growth (this year): | 2.87% | Revenue Growth (next year): | -25.97% |
Latest ProQR Therapeutics N.V. News
PRQR Breaking Stock News: Dive into PRQR Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating
GlobeNewswire
10 days ago
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
Simply Wall St.
13 days ago
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)
GlobeNewswire
14 days ago
ProQR Announces First Quarter 2025 Operating and Financial Results
GlobeNewswire
20 days ago
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
GlobeNewswire
21 days ago
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
TipRanks
23 days ago
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald
TipRanks
23 days ago
ProQR Therapeutics initiated with an Outperform at Evercore ISI
Compare PRQR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.